Exosomes and stem cells are different things. A stem cell is a living cell that can divide and, under the right conditions, become other kinds of cells, while an exosome is a tiny bubble of membrane that a cell releases, carrying proteins, fats and RNA but no nucleus and no ability to grow or divide.
The confusion is understandable, because many exosome products are collected from stem cells grown in a laboratory, and product names often mention both. This guide explains what each one is, how each is made, why the FDA regulates them along different paths, and which questions help you understand what a provider is offering.
Where the FDA stands
The FDA stated in its 2019 public safety notification, and again in its consumer alert on regenerative medicine products, that there are no FDA-approved exosome products. The same consumer alert states that, generally, all stem cell products require FDA approval. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats, and whether any product suits a given person is a decision for that person and their own licensed provider.
Understanding stem cells as living cells that divide and specialize
A stem cell is a whole, living cell with a nucleus, its own DNA and the machinery to copy itself. The stem cells most often discussed in aesthetic and regenerative settings are mesenchymal cells, which researchers isolate from tissues such as bone marrow, fat and umbilical cord.
Pittenger and colleagues reviewed this cell type in 2019 and reported that it can become other cell types under defined laboratory conditions, but only in limited situations after placement in the body. They also counted more than 950 clinical trials investigating these cells, which shows how actively the field is still being studied.
Even the name is debated. In a 2019 position statement led by Viswanathan, the mesenchymal stromal cell committee of the ISCT, an international cell science society, recommended that these cells be called mesenchymal stromal cells unless rigorous evidence of true stem cell behavior exists, and that the tissue of origin always be named, so you may see both terms in product literature.
Understanding exosomes as vesicles released by cells
Many kinds of cells release tiny membrane packages into the fluid around them. Scientists call the whole family extracellular vesicles, and exosomes are one kind, formed inside the cell in compartments called endosomes before being released, as Raposo and Stoorvogel described in 2013.
Kalluri and LeBleu reviewed exosome biology in Science in 2020 and described an average diameter of about 100 nanometers, with a cargo of nucleic acids, proteins, lipids and metabolites that reflects the cell that released them. A nanometer is one millionth of a millimeter, so an exosome is far too small to see with an ordinary microscope.
The International Society for Extracellular Vesicles defines these particles in its MISEV2023 guideline as released from cells, wrapped in a lipid bilayer, and unable to replicate on their own because they contain no functional nucleus. That definition is the plainest answer to the question of whether exosomes are stem cells: an exosome comes from a cell, and it has none of the parts a cell needs to live or multiply.
Comparing exosomes and stem cells side by side
| Feature | Stem cells (mesenchymal) | Exosomes (extracellular vesicles) | Source |
|---|---|---|---|
| What it is | A whole, living cell | A membrane vesicle released by a cell | Pittenger 2019; MISEV2023 |
| Nucleus and DNA | Yes, a full nucleus | No functional nucleus | MISEV2018; MISEV2023 |
| Can it divide or grow? | Yes, it can be expanded in culture | No, it cannot replicate on its own | Pittenger 2019; MISEV2023 |
| Typical size | A whole cell, many times larger than a vesicle | About 100 nanometers on average | Kalluri 2020 |
| What it carries | Everything a living cell contains | Proteins, lipids, RNA and metabolites from the parent cell | Kalluri 2020; Raposo 2013 |
| How it is described | By tissue source and cell behavior | By size, concentration, markers and parent cell | Viswanathan 2019; Witwer 2019 |
| Federal category | An HCT/P, sorted into the 361 or 351 pathway by four criteria | Regulated as a drug and biological product when used for a disease or condition | 21 CFR 1271.3 and 1271.10; FDA 2019 |
| FDA-approved examples | Cord blood products (including OMISIRGE), one stromal cell product (RYONCIL, 2024) and gene-modified blood stem cell products | None | FDA approved products list, 30 October 2026; FDA 2019 |
The table shows why the two are discussed together and also why they are kept apart. They share an origin, since stem cells are a common source of exosomes, and they differ in almost every property that matters for making, testing and regulating a product.
Understanding how each product is made in the laboratory
A stem cell product starts with donated tissue. The cells are separated from that tissue, grown in culture to expand their numbers, and then kept alive through processing, storage and shipment, because the product is the living cell itself.
An exosome product usually starts the same way and then takes a different turn. Cells are grown in culture, the fluid they release vesicles into is collected, and the vesicles are separated from that fluid and from the cells; the MISEV2018 guideline describes repeated low-speed spins in which the cells collect at the bottom of the tube, followed by faster spins that gather the vesicles.
Because the source cells shape the final material, quality depends on careful records. Witwer and colleagues, writing for four scientific societies in 2019, reported that differences in source cells, production methods and testing have produced inconsistent results, and they called for each vesicle preparation to be defined by measurable features of its cell of origin, its membrane vesicles and their integrity.
Gimona and colleagues, who run a manufacturing unit for vesicle products, wrote in 2017 that the source cell type shapes the manufacturing, safety and testing requirements. They also wrote that vesicles from stem and progenitor cells may have effects comparable to their parent cells, while identifying exactly how they work remains a major challenge.
Understanding why exosome material contains no living cells
The MISEV2023 guideline instructs researchers to remove cells from all vesicle source material as early as possible in processing. Its authors explain that broken cells can form particles that resemble vesicles and that living cells left in a sample can keep changing it, so a well-made vesicle preparation is cell-free from the start.
This is the practical meaning of the phrase cell-free. Park GH and colleagues noted in their 2023 skin study that concerns such as low engraftment and a rare risk of abnormal growth have limited the use of whole stem cells, and they described adipose stem cell-derived exosomes as a cell-free alternative for research.
For a patient, the takeaway is simple. Exosome material may come from stem cells, and the vial holds the vesicles those cells released, along with the solution they are stored in, with no living cells inside.
Regulation separates cell products from cell-released products
Federal rules for human cell and tissue products sit in 21 CFR part 1271. Section 1271.3(d) defines these products, called HCT/Ps, as articles containing or consisting of human cells or tissues intended for implantation, transplantation, infusion or transfer into a person, and it lists secreted or extracted human products such as milk, collagen and cell factors among the articles that are not HCT/Ps.
A cell product that meets all four criteria in section 1271.10 is regulated under section 361 of the Public Health Service Act, with registration, donor screening and handling rules but no premarket approval. The criteria are minimal manipulation, homologous use, no combination with another article apart from listed exceptions, and either no systemic effect and no dependence on living cells for its main function or one of three listed uses, and the FDA explains the first two in its 2017 guidance revised in 2020.
A product that misses any criterion is regulated as a drug, device or biological product, and cell products in this group are generally licensed as biological products under section 351, which requires FDA review before marketing. Most cultured stem cell products fall here, and the FDA list of approved cellular and gene therapy products, current as of 30 October 2026, shows how few have completed that path.
The stem cell products on that list are nine cord blood products (HPC, Cord Blood); OMISIRGE, a cord blood product expanded in the laboratory; one mesenchymal stromal cell product, RYONCIL, licensed in December 2024 for a single narrowly defined use in children; TREGZI, which pairs donor blood-forming stem and progenitor cells with donor immune cells for use in a stem cell transplant; and seven gene-modified products made from a patient’s own blood-forming stem cells: CASGEVY, KRESLADI, LENMELDY, LYFGENIA, SKYSONA, WASKYRA and ZYNTEGLO.
The same list holds cell products that are not stem cell products: MACI (cultured cartilage cells), LANTIDRA (pancreatic islet cells), RETHYMIC (processed thymus tissue), ENCELTO (encapsulated cells placed in the eye), the skin cell products GINTUIT, LAVIV, STRATAGRAFT and ZEVASKYN, and the immune cell products ABECMA, AMTAGVI, AUCATZYL, BREYANZI, CARVYKTI, KYMRIAH, PROVENGE, TECARTUS, TECELRA and YESCARTA. The remaining entries are gene therapies and one acellular engineered vessel, and no exosome product appears on the list.
Exosomes contain no cells, so the HCT/P route does not describe them. The FDA stated in 2019 that, as a general matter, exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products and are subject to premarket review and approval requirements, and the agency reports that no exosome product has been approved.
| Pathway | Who it covers | Premarket FDA approval? | Source |
|---|---|---|---|
| Section 361 HCT/P | Cell and tissue products meeting all four criteria in 1271.10 | No; registration, listing and handling rules apply | 21 CFR 1271.10; FDA 2020 guidance |
| Section 351 biologic | Cell products that miss a criterion, including most cultured stem cell products | Yes, a biologics license | 21 CFR 1271.10; FDA approved products list |
| Drug and biological product | Exosome products used for a disease or condition, as the FDA describes them | Yes; none approved to date | FDA 2019 notification; FDA consumer alert |
Understanding the FDA safety notices on unapproved products
The FDA has issued public warnings about both product types. Its 2019 notification described multiple reports of serious adverse events in Nebraska among patients given unapproved products marketed as containing exosomes, and it noted that some clinics already selling violative stem cell products had begun offering exosome products too.
The published record on unproven stem cell interventions is longer. Bauer, Elsallab and Abou-El-Enein reviewed scientific papers, case reports and media reports in 2018 and documented adverse events after stem cell interventions offered outside controlled trials, and Kuriyan and colleagues reported in 2017 that three patients lost much of their vision after eye injections of their own fat-derived cells at one US clinic.
Senior FDA officials, including the then Commissioner, addressed the benefits and risks of stem cell products in the New England Journal of Medicine in 2017. The agency asks patients to check whether the FDA has reviewed a product and to report problems through its MedWatch program, and that advice applies equally to stem cell and exosome products.
Comparing exosomes and stem cells for skin
Most published aesthetic research on exosomes uses them on the surface of the skin, often right after a procedure such as microneedling. Park GH and colleagues ran a split-face study of 28 participants in 2023, with exosome solution on one side and saline on the other after each microneedling session, and reported higher appearance scores on the exosome side with no serious adverse events observed.
Gaebe and colleagues reviewed 16 vesicle studies with 503 participants in 2026. They reported that most found improvement in at least one skin-quality measure without serious adverse events, and they rated the certainty of that evidence as low or very low.
Live stem cells sit in a different category for skin. The FDA consumer alert states that, generally, all stem cell products require FDA approval, so a living cell product offered for appearance would need that review, while topical exosome material is a separate category handled by the practitioner who selects it.
People often ask whether exosomes are better than stem cells. The sources reviewed for this guide include no study comparing the two head to head in people, so the honest answer is that they are different materials with different evidence, and a licensed provider is the right person to discuss which, if either, fits a plan.
Understanding what the evidence does not yet show
Both fields are young, and the researchers who know them best say so. The limits below come straight from the reviews and guidelines cited here.
- No head-to-head human comparison: none of the sources reviewed for this guide compares exosomes with stem cells in the same people.
- Low-certainty skin evidence: Gaebe and colleagues rated the vesicle studies for facial appearance as low or very low certainty in 2026, with short follow-up.
- Variable products: Witwer and colleagues reported in 2019 that source cells, production methods and testing differ widely, so a result for one product may not apply to another.
- Unsettled mechanism: Gimona and colleagues wrote in 2017 that identifying how vesicles from stem cells work remains a major challenge.
- Changing names: Viswanathan and colleagues recommended in 2019 that the word stem be reserved for cells with rigorous evidence of stem cell behavior, so product names vary.
Each limit also points to a clear next step. Better characterized products, shared standards such as MISEV2023, and larger studies with longer follow-up are all moving the field toward firmer answers.
Questions to ask your provider
Good practices welcome these questions. Each follows from an FDA source or a guideline cited in this guide.
- Is this product made of living cells, or of vesicles released by cells?
- Which cells and which tissue was the material made from, and who manufactured it?
- Has the FDA reviewed this product, and if it is part of a study, what is the IND number, as the FDA suggests patients ask?
- What does the product labeling state about how and where the material was made?
- Can I see the lot number and the certificate of analysis for the material used in my visit?
- How was the product shipped and stored before it reached the clinic?
- Who do I contact with a concern afterward, and how would a problem be reported to the FDA through MedWatch?
Documenting exosome material in the practice record
A practice can answer the questions above from one file. MISEV2023 sets out how vesicle material should be characterized by size, concentration, marker proteins and appearance under a microscope, and a certificate of analysis organized under those headings shows that the material is a vesicle preparation and records where it came from.
ExaVeyra exosome material ships frozen from the manufacturing facility in all available formats, and every vial carries its lot number. A certificate of analysis is generated for every lot and is available on request, together with the characterization panel and cold-chain records; every ExaVeyra certificate reports serological testing for pathogens, and miRNA characterization data is available on request.
Looking ahead with clearer language and better records
Knowing that an exosome is a vesicle and a stem cell is a living cell clears up much of the confusion in this field. Patients who ask what a product is made of, and practices that keep clear records, both help the research and the regulation move forward on firm ground.
ExaVeyra supplies characterized exosome material to licensed practitioners, with the lot documents that make these conversations easy. Anyone may ask the scientific team a question or apply without an NPI, and NPI verification gives access to the practitioner portal, exclusive resources and pricing. The product names in this guide and its references are trademarks of their respective owners.
Aviso Educativo: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Referencias
- 1.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline, compiled with expert task forces and feedback from more than 1,000 researchers. Carries in this article: the definition of extracellular vesicles as particles released from cells, delimited by a lipid bilayer, that cannot replicate on their own because they contain no functional nucleus; the advice to remove cells from source material as early as possible in processing; and the characterization headings a certificate of analysis can follow. Disclosure: many consortium authors list vesicle company affiliations, declared in the article.
- 2.Théry C, Witwer KW, Aikawa E, Alcaraz MJ, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. PMID 30637094. PMC6322352. doi:10.1080/20013078.2018.1535750International society position statement and reporting guideline. Carries in this article: extracellular vesicle as the umbrella term covering exosomes, microvesicles and other cell-released particles; the same no-functional-nucleus definition; and the separation steps (repeated low-speed spins that pellet the cells, then faster centrifugation) that take vesicles away from the cells that released them. Disclosure: consortium authors list academic and company affiliations, declared in the article.
- 3.Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. PMID 32029601. PMC7717626. doi:10.1126/science.aau6977Narrative review in Science. Carries in this article: exosomes are a subset of extracellular vesicles with an average diameter of about 100 nanometers, they begin inside the cell in compartments called endosomes, and their cargo of nucleic acids, proteins, lipids and metabolites reflects the cell that released them. Disclosure: the PubMed competing interests statement reports exosome patents held by the senior author and his institution and licensed to an exosome company, plus equity or paid consulting ties with that company for both authors.
- 4.Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373-383. PMID 23420871. PMC3575529. doi:10.1083/jcb.201211138Narrative review of vesicle formation and function. Carries in this article: exosomes form inside the cell (endosomal origin) while microvesicles bud from the outer membrane, and both carry membrane and internal proteins, lipids and RNA between cells as a form of cell-to-cell communication. Disclosure: academic authors; no COI statement in the PubMed record.
- 5.Pittenger MF, Discher DE, Péault BM, Phinney DG, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019;4:22. PMID 31815001. PMC6889290. doi:10.1038/s41536-019-0083-6Narrative review. Carries in this article: MSC is the shared acronym for cells called mesenchymal stem cells, stromal cells or progenitor cells; they can become other cell types under defined laboratory conditions and only in limited situations after implantation; they were first described about 30 years before the review; and more than 950 clinical trials were investigating them. Disclosure: one author founded Longevity Therapeutics, one holds equity in and consults for Longeveron and Vestion, and one is a co-inventor on MSC intellectual property (competing interests statement).
- 6.Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019-1024. PMID 31526643. doi:10.1016/j.jcyt.2019.08.002International society committee position statement. Carries in this article: the committee recommends calling these cells mesenchymal stromal cells unless rigorous laboratory and animal evidence of stemness exists, and naming the tissue they came from, which is why the names in product literature vary. The statement does not itself survey how often the word stem is misused. Disclosure: no COI statement in the PubMed record.
- 7.Witwer KW, Van Balkom BWM, Bruno S, Choo A, Dominici M, Gimona M, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019;8(1):1609206. PMID 31069028. PMC6493293. doi:10.1080/20013078.2019.1609206Joint position paper of four societies (SOCRATES, ISEV, ISCT and ISBT). Carries in this article: differences in source cells, production and separation methods, and the lack of standard quality assays have produced inconsistent results, so vesicle preparations from MSCs should be defined by measurable features showing their cell of origin, the presence of membrane vesicles and their integrity. Disclosure: several authors list company affiliations, declared in the article.
- 8.Gimona M, Pachler K, Laner-Plamberger S, Schallmoser K, Rohde E. Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use. Int J Mol Sci. 2017;18(6):1190. PMID 28587212. PMC5486013. doi:10.3390/ijms18061190Narrative review from a GMP manufacturing unit. Carries in this article: vesicle manufacturing, safety and testing requirements are shaped by the source cell type; the authors wrote that vesicles from stem and progenitor cells may have effects comparable to their parent cells, and that identifying how they work remains a major challenge. Disclosure: the authors declared no conflict of interest.
- 9.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the reports of serious adverse events in Nebraska among patients given unapproved products marketed as containing exosomes; the statement that there are currently no FDA-approved exosome products; the statement that, as a general matter, exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products subject to premarket review; that some clinics selling violative stem cell products were also offering exosome products; and the advice to ask whether the FDA has reviewed a product and to report problems through MedWatch.
- 10.U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Dated July 22, 2020; content current as of 04/09/2024; verified 9 November 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesAgency consumer alert (CBER). Carries in this article: the FDA regulates both stem cell products and exosome products; generally all stem cell products require FDA approval; the alert's statement that the only FDA-approved stem cell products are cord blood products dates from July 2020 and predates later approvals, so the article does not repeat it; there are no FDA-approved exosome products; and readers are asked to report problems to MedWatch.
- 11.U.S. Food and Drug Administration. 21 CFR 1271.3, How does FDA define important terms in this part? Text verified on eCFR 9 November 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1271.3 and https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.3Federal regulation, definitions. Carries in this article: paragraph (d) defines HCT/Ps as articles containing or consisting of human cells or tissues intended for implantation, transplantation, infusion or transfer into a human recipient, and lists articles that are not HCT/Ps, including secreted or extracted human products such as milk, collagen and cell factors.
- 12.U.S. Food and Drug Administration. 21 CFR 1271.10, Are my HCT/Ps regulated solely under section 361 of the PHS Act and the regulations in this part? Text verified on eCFR 9 November 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1271.10 and https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.10Federal regulation. Carries in this article: the four cumulative criteria (minimal manipulation, homologous use, no combination with another article apart from listed exceptions, and either no systemic effect and no dependence on living cells' metabolic activity or one of three listed uses) that an HCT/P must meet to be regulated solely under section 361; a product that misses any one of them is regulated as a drug, device or biological product (21 CFR 1271.20).
- 13.U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. Guidance for industry and FDA staff, November 2017, revised July 2020 (content current as of 07/21/2020; verified 9 November 2026). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimalAgency guidance (CBER and CDRH), docket FDA-2017-D-6146. Carries in this article: the FDA's current thinking on the minimal manipulation and homologous use criteria in 21 CFR 1271.10, the two tests most often discussed when a cell or tissue product is sorted into the 361 or the 351 pathway.
- 14.U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Content current as of 10/30/2026; verified 9 November 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-productsAgency list of licensed products from the Office of Therapeutic Products. Carries in this article: the stem cell products on the list are nine HPC, Cord Blood products, OMISIRGE (omidubicel-onlv, expanded cord blood), RYONCIL (remestemcel-L-rknd), TREGZI (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) and seven gene-modified autologous hematopoietic stem cell products (CASGEVY, KRESLADI, LENMELDY, LYFGENIA, SKYSONA, WASKYRA, ZYNTEGLO; HSC basis confirmed in each DailyMed label description); the non-stem cell products named in the body (MACI, LANTIDRA, RETHYMIC, ENCELTO, GINTUIT, LAVIV, STRATAGRAFT, ZEVASKYN, ABECMA, AMTAGVI, AUCATZYL, BREYANZI, CARVYKTI, KYMRIAH, PROVENGE, TECARTUS, TECELRA, YESCARTA); the remaining entries are gene therapies and the acellular SYMVESS; no exosome product appears on the list.
- 15.U.S. Food and Drug Administration. RYONCIL (remestemcel-L-rknd). Approval letter December 19, 2024; content current as of 01/17/2025; verified 9 November 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/ryoncilAgency product page, STN 125706, manufacturer Mesoblast, Inc. Carries in this article: the first mesenchymal stromal cell product on the FDA approved list, licensed in December 2024 for one narrowly defined indication in children, an example of the full biologics licensing route that a cell product can complete.
- 16.Marks PW, Witten CM, Califf RM. Clarifying Stem-Cell Therapy's Benefits and Risks. N Engl J Med. 2017;376(11):1007-1009. PMID 27959704. doi:10.1056/NEJMp1613723Perspective article by the then FDA Commissioner and two senior CBER officials. Carries in this article: senior FDA officials addressed the benefits and risks of stem cell products in a leading medical journal in 2017, a sign of how closely the agency follows this market. Disclosure: authors were FDA officials; no commercial funding.
- 17.Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018;7(9):676-685. PMID 30063299. PMC6127222. doi:10.1002/sctm.17-0282Review of scientific publications, clinical case reports and mass media reports of adverse events after unproven stem cell interventions, with an analysis of what drives stem cell tourism. Carries in this article: harms have been documented after unproven stem cell interventions given outside controlled trials. Disclosure: academic authors; no COI statement in the PubMed record.
- 18.Kuriyan AE, Albini TA, Townsend JH, Rodriguez M, et al. Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. N Engl J Med. 2017;376(11):1047-1053. PMID 28296617. PMC5551890. doi:10.1056/NEJMoa1609583Case series of three patients evaluated at academic eye centers. Carries in this article: three patients developed severe vision loss in both eyes after eye injections of their own fat-derived cells marketed as stem cells at one US clinic, and one year later their vision ranged from 20/200 to no light perception. Disclosure: no COI statement in the PubMed record.
- 19.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face comparative study; three microneedling sessions three weeks apart with exosome solution on one side and saline on the other, follow-up 6 weeks after the last session; Korean dermatology centers; n = 28. Carries in this article: an example of the topical, cell-free design; the authors' background statement that low engraftment and a rare risk of abnormal growth have limited the use of whole stem cells; higher appearance scores on the exosome side with no serious adverse events observed. Disclosure: the PubMed record lists National Research Foundation of Korea grants and no COI statement.
- 20.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026 Jul 22. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches to June 2025; 16 studies, 503 participants. Carries in this article: most studies reported improvement in at least one skin-quality measure and no serious adverse events, while risk of bias was moderate to critical, certainty was low or very low, and follow-up was short. Disclosure: academic authors (Canada); no COI statement in the PubMed record.